Core Viewpoint - The company aims to enhance its internationalization strategy and brand influence by signing an exclusive supply agreement with GOODFELLOW PHARMA CORPORATION for the product Efparepoetin alfa in the Philippines [1][6]. Summary by Sections Agreement Overview - The board of directors approved the exclusive supply agreement with GOODFELLOW for the product Efparepoetin alfa, which is currently under registration [2]. - The agreement does not involve related party transactions or constitute a major asset restructuring [2][3]. Product Information - Efparepoetin alfa is a new biological drug intended for treating anemia in adult dialysis patients due to chronic kidney disease (CKD) and has submitted a listing application [2]. - As of June 30, 2025, the cumulative R&D investment in Efparepoetin alfa is approximately 498.92 million yuan [2]. Partner Information - GOODFELLOW PHARMA CORPORATION, established in 2004, is based in Metro Manila, Philippines, and specializes in the import and export of medical products [3][4]. - There is no related party relationship between GOODFELLOW and the company [4]. Agreement Details - GOODFELLOW is authorized as the exclusive agent in the Philippines for the registration, clinical trials, promotion, distribution, and sales of Efparepoetin alfa [4][5]. - The agreement includes provisions for product registration, with the company responsible for preparing necessary documentation and providing product samples for clinical research [5]. - The agreement is effective for five years from the date of obtaining the import drug license, with a potential five-year extension [5][6]. Impact on the Company - This transaction represents a significant step in the company's internationalization strategy, expected to generate economic benefits and enhance brand value [6][7]. - The collaboration aims to expedite the commercialization of R&D results and expand the overseas market for Efparepoetin alfa, thereby improving the company's performance [7].